VS-01 is under clinical development by Genfit and currently in Phase II for Acute On Chronic Liver Failure (ACLF). According to GlobalData, Phase II drugs for Acute On Chronic Liver Failure (ACLF) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VS-01 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VS-01 overview
VS-01 is under development for the treatment of acute-on-chronic liver failure (ACLF) (hepatic encephalopathy), ascites, organic acidemia disorder (OAD) and urea cycle disorders such as hyperammonemia. The drug candidate is a sterile, white liposomal suspension containing citric acid developed as peritoneal dialysis fluid. It is administered through the intraperitoneal route. It was also under development for decompensated liver cirrhosis.
Genfit overview
Genfit is a late-stage biopharmaceutical company. It develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include VS-01-ACLF, nitazoxanide (NTZ), inhibitor SRT-015, CLM-022, VS-02-HE, GNS561, VS-01-HAC, TS-01 and NIS2+. Genfit’s products are used in various therapeutic areas including acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemias (OA). Its products include diagnostic tools for non-alcoholic steatohepatitis (NASH) and ammonia. The company works in collaboration with Genoscience Pharma, Ipsen Pharma, Seal Rock Therapeutics, Celloram, Labcorp, and Terns Pharmaceuticals for research and development. Genfit is headquartered in Loos, Hauts-de-France, France.
For a complete picture of VS-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
